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Abstract  
Aims: To assess associations of comorbidity patterns observed in people living with HIV 
(PLWH) with risk factors and health outcomes. 
Methods: Common patters of comorbidities in PLWH participating in the POPPY study were 
determined using principal component analysis and a severity score for each pattern was derived. 
Associations between each pattern’s severity score and risk factors were assessed using median 
regression. The independent associations of patterns’ severity scores with self-reported physical 
and mental health (SF-36 summary scores) were assessed using linear regression, with functional 
impairment (Lawton IADL<8) and hospitalization in last year using logistic regression and with 
number of general practitioner (GP) visits using Poisson regression.    
Results: 1073 PLWH were analysed: 85.2% male, median (IQR) age 52 (47-59) years, 98% on 
therapy. Duration of HIV was associated with higher severity in 4/6 of patterns: cardiovascular 
diseases (CVD), mental health problems, metabolic disorders and chest/other infections (all 
p’s≤0.001). Prior AIDS was associated with higher severity scores for the same patterns and for 
the pattern of cancers (p<0.001). CVD was associated with poorer physical health (p=0.02), 
higher risk of functional impairment (p=0.02) and hospitalization (p<0.001) and with higher 
number of GP visits (p<0.001). Severity of mental health (all p’s<0.001) and of chest/other 
infections patterns negatively affected all the five health outcomes.  
Conclusion: Common patterns of comorbidities seen in PLWH appear to have different risk 
factors and to differently affect health outcomes. These findings may assist the development of 
targeted intervention to prevent, treat and manage the increasingly prevalent multimorbidity in 
PLWH.   
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Introduction  
The widespread use of combination antiretroviral treatment (cART) has led to an increase in 
life expectancy of people living with HIV (PLWH) in many regions of the world [1], 
resulting in major demographic changes that are expected to continue. For example, studies 
have estimated that up to 73% of PLWH in the Netherlands will be aged 50 years or older in 
2030 [2], with similar proportions in Italy and the USA [3]. As a result, PLWH are 
experiencing an increasing burden of comorbidities [4] that is also expected to further 
increase; the same studies have estimated that the proportions of PLWH with at least one 
comorbidity would reach 84% in the Netherlands by 2030 and 89% in Italy and the USA by 
2035.    
We have reported a tendency for comorbidities to co-occur in the same HIV-positive 
individual at prevelances that are higher than those expected by chance alone and to occur in 
specific patterns [5]. Whilst knowledge of frequent patterns of comorbidities could inform 
decisions for prevention strategies, a better understanding of the mechanistic basis underlying 
these patterns and the burden they pose on PLWH and on the healthcare system is required.  
Both in the general population and in populations of PLWH, most of the research published 
to date has focused on determinants of multimorbidity rather than of specific patterns. Among 
PLWH, studies have reported associations of multimorbidity with age and obesity [6], 
smoking [7] and duration of HIV infection [8, 9]. However, considering the diverse nature of 
conditions and comorbidities that could be encompassed into a definition of multimorbidity, 
these findings are unlikely to provide generalizable evidence of the causes underlying 
specific patterns. The two previous studies that focused on data-driven patterns of 
comorbidities in PLWH only investigated associations with one selected factor: Goulet et al. 
[10] found hepatits C virus co-infection to be associated with patterns of mental health 
problems and alcohol-related complications, while Kim et al. [11] reported an association of 
obesity with metabolic and behavioral problems. Little is known about the impact of HIV-
related factors and other non-HIV-related modifiable and non-modifiable factors on specific 
patterns of comorbidities commonly seen in PLWH. 
Similarly, whilst there is some evidence of the impact of multimorbidity on health outcomes 
such as quality of life of PLWH [12] and healthcare costs [13], there are no data on the 
impact of specific patterns of comorbidities to reveal those with the greatest burden for both 
patients and the healthcare system. Different patterns of comorbidities can be expected to 
differentially affect quality of life and use of healthcare resources. Moreover, the effect of a 
certain pattern can be greater (or lower) than the sum of the independent effects of all 
comorbidities within the pattern. 
The aims of this study were (i) to investigate HIV-related and non-HIV-related risk factors 
for common patterns of comorbidities observed in PLWH seen for care in the UK and 
Ireland, and (ii) to evaluate associations of each pattern with self-reported health outcomes 
such as quality of life, functional impairment and healthcare resource use.  
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Methods 
Study participants 
The Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study is an 
observational study that aims to examine the effects of ageing on the clinical outcomes of 
PLWH in the UK and Ireland. Full details have been described previously [14]. Briefly, two 
cohorts of PLWH were recruited from eight HIV outpatient clinics in London, Brighton (UK) 
and Dublin (Ireland) between April 2013 and January 2016: an ‘older’ group of PLWH aged 
≥50 years and a younger group of PLWH aged between 18 and 50 years. Inclusion criteria 
were: documented presence of HIV infection, white or black-African ethnicity, likely route of 
HIV acquisition via sexual exposure and ability to comprehend the study information leaflet. 
The younger group of PLWH was frequency matched on gender, ethnicity, sexual orientation 
and location (in or out of London) to the older PLWH. In addition, the study recruited a 
group of HIV-negative individuals aged ≥50 years which was not included in the present 
analysis. These inclusion criteria were selected to ensure that study participants were 
representative of the wider population of PLWH over the age of 50 in the UK and Ireland, as 
has previously been shown [14]. The study was approved by the UK National Research 
Ethics Service (NRES; Fulham London, UK number 12/LO/1409). All participants provided 
written informed consent. 
Patterns of comorbidities 
We considered a list of 65 individual comorbidities (see Supplementary Table 1) obtained as 
follows. Full clinical history, medications and healthcare resources used over the year 
preceding the study visit were obtained via a structured interview with trained staff who, 
where possible, also reviewed hospital notes to validate the presence of comorbidities. 
Participants were asked whether they ever experienced any of the comorbidities or medical 
conditions from a detailed list and to report any other relevant comorbidity not included in 
the initial list. Answers to these free-text questions, reasons for any healthcare utilization over 
the previous year, and use of (non-antiretroviral) medication in the previous year were also 
examined to update the existing list of comorbidities or to include additional ones. Congenital 
diseases and conditions with a prevalence <1.5% () in the study population were 
subsequently excluded.  
As previously described [5], principal component analysis (PCA) with oblimin rotation was 
applied to the matrix containing the pairwise associations (as measured by the Somers’ D) 
between the 65 comorbidities. Six components (i.e. patterns) were extracted as suggested by 
very simple structure criterion [15] and comorbidities associated with each pattern (i.e. with a 
correlation >0.40) were reported. For each participant and each pattern, a severity score for 
that pattern was obtained using data on the presence/absence of comorbidities and 
coefficients returned by the PCA (rescaled so that the lowest score is 0). Severity scores were 
proportional to the number of comorbidities included in the pattern that were present in an 
individual, with higher scores indicating a greater number of comorbidities characterising the 
pattern. 
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Risk factors  
We considered a range of potential risk factors for each comorbidity pattern, including socio-
demographic, lifestyle and HIV-specific characteristics. Age, gender, ethnicity, sexual 
orientation (MSM or heterosexual), previous/current smoking and alcohol consumption, 
current recreational drug use (within the six months preceding study visit) and history of 
injection drug use were self-reported by study participants via a structured interview. Body 
mass index (BMI) was also measured at study visit and historical data on HIV-specific 
parameters were obtained via linkage with the UK CHIC study [16] and the Mater 
Misericordiae University Hospital Infectious Diseases cohort for participants recruited in 
Ireland [17]. Years since HIV diagnosis, nadir CD4+ T cell count and prior AIDS (defined as 
a previous report of a category C event [18]) were considered as potential risk factors. 
Health outcomes 
Five health-related outcomes were considered: patient-reported physical and mental health, 
number of GP visits, hospitalisation and functional impairment. Physical and mental health 
summary scores were obtained from the Short Form Health Survey (SF-36) questionnaire 
[19]. Briefly, scores for eight subscales (physical functioning, physical limitation, emotional 
limitation, energy/fatigue, emotional well-being, social functioning, pain and general health) 
were derived as recommended by the developers of the SF-36 [284] and then standardized 
into z-scores (with a mean of 0 and a standard deviation of 1) using gender- and age-specific 
means and standard deviations obtained from the 1996 Health Survey for England (HSE) 
dataset [285]. Standardized scores were then combined to obtain the two summary scores of 
physical and mental health and re-scaled to have a mean of 50 and a standard deviation of 10. 
Functional impairment was assessed using the Lawton IADL tool [20] and defined as 
impairment in ≥1 activity of daily living. The number of GP visits and hospitalization (yes or 
no) in the year preceding study visit were derived from information collected on healthcare 
resource use. 
Statistical analysis 
For each pattern’s severity score, a multivariable median regression model was fitted to 
assess the independent associations with risk factors previously described. Associations of 
socio-demographic, lifestyle and HIV-specific factors with each pattern’s severity score are 
reported as associated average change (with 95% confidence interval) in the median severity 
score. 
The independent associations of each pattern severity score and each health-related outcome 
considered were assessed using a different multivariable model, depending on the type and 
distribution of the outcome. In each model, all pattern severity scores were added 
simultaneously to account for the correlations between the scores. For physical and mental 
health summary scores, linear regression models were used and regression coefficients (β: 
average increase/decrease in the physical/mental score associated with a one-unit increase in 
the severity score of a pattern, while holding all other severity scores constant) are reported. 
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Logistic regression was used for hospitalization and functional impairment and odds ratios 
(ORs) are reported. The number of GP visits was analyzed using Poisson regression and 
incident risk ratios (IRRs) associated with a one-unit increase in severity scores are reported. 
All analyses were performed using the statistical software R v3.3.3; p-values <0.05 were 
considered statistically significant.  
Results 
Characteristics of study participants 
A total of 1073 PLWH were recruited into the POPPY study: 699 older and 374 younger 
PLWH. Socio-demographic and HIV-related characteristics are summarised in Table 1. 
Participants were predominantly male (85.2%), of white ethnicity (84.1%), men who have 
sex with men (MSM: 76.0%) with a median (interquartile range: IQR) age of 52 (47, 59). The 
median (IQR) CD4+ T-cell count was 624 (475, 811) cells/L and 89.9% had a suppressed 
viral load (<50 copies/mL). Current smoking was reported by 24.9% of study participants, 
current recreational drug use and history of injection drug use were reported by 28.6% and 
10.5%, respectively.        
The numbers of participants with completed information on the five health outcomes were 
886 for SF-36 physical and mental health scores, 1020 for functional impairment and 1073 
for number of GP visits and hospitalization in the last year. The median (IQR) physical and 
mental health score were 52.4 (42.3, 56.3) and 51.0 (41.6, 57.2), respectively. Functional 
impairment was observed in 14.5% of PLWH, 65.0% had been hospitalized in the year 
preceding the study visit and the median (IQR) number of GP visits was 1 (1, 2). 
Patterns of comorbidities 
The prevalence of individual comorbidities is reported in Supplementary Table 1. The six 
patterns obtained using the PCA are described in Figure 1, with full details reported 
elsewhere [5]. The patterns were termed as follow: cardiovascular disease (CVD), sexually 
transmitted diseases (STDs), mental health problems, cancers, metabolic disorders and chest 
problems and other infection. 
The distribution, with median and (IQR), of the severity scores of the six patterns in study 
participants are reported in Figure 1. Highest severity scores were observed for the STDs 
pattern with a median (IQR) of 1.34 (0.01, 2.83). There was high variability on the metabolic 
and mental health pattern scores, with PLWH reporting either very low or relatively high 
scores. The distribution of CVD and cancer severity scores were similar, with only a small 
proportion of individuals reporting extremely high scores compared to the majority of 
PLWH. There was less variability in the severity scores for the chest/other infections pattern 
for which the median (IQR) score was 0.17 (0.03, 0.34). 
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Risk factors of patterns of comorbidities 
Older age [0.06 (0.04, 0.07) per each 10-year older, p<0.001], greater BMI [0.03 (0.01, 0.05) 
per 5-kg/m2 increment, p=0.009], longer time since HIV diagnosis [0.04 (0.02, 0.06) per 10-
year increment, p<0.001] and prior AIDS [0.08 (0.04, 0.12), p<0.001] were independently 
associated with higher CVD severity scores (Table 2). MSM [1.45 (1.33, 1.57), p<0.001] and 
those with a history of injection drug use [1.24 (0.64, 1.84), p<0.001] had significantly higher 
severity scores for the STD pattern compared to heterosexuals and those who never reported 
using injection drugs, respectively. Mental health severity scores were significantly 
associated with injection drug use [1.27 (0.87, 1.66), p<0.001], longer time since HIV 
diagnosis [0.14 (0.07, 0.21) per 10-year increment, p<0.001] and prior AIDS [0.15 (0.04, 
0.26), p=0.007]. Women also appeared to have higher mental health scores [0.12 (0.01, 0.23), 
p=0.03] than men.  
The cancer and metabolic pattern scores were each significantly associated with older age 
(both p’s<0.001) and greater BMI (p=0.03 and p=0.006, respectively). In addition, cancer 
scores were significantly higher in MSM [0.06 (0.02, 0.09), p=0.005] than in heterosexuals 
and those with prior AIDS [0.15 (0.12, 0.19), p<0.001], whilst the associations with nadir 
CD4+ T cell count and time since HIV diagnosis did not reach statistical significance (p=0.08 
and p=0.09, respectively). On the other hand, metabolic scores appeared to be significantly 
associated with longer time since HIV diagnosis [0.11 (0.05, 0.16) per 10-year increment, 
p<0.001], prior AIDS (p=0.05) and nadir CD4+ T cell count p=0.07). Finally, older age 
(p<0.001), prior AIDS (p<0.001) and a longer time since HIV diagnosis (p=0.001) were all 
independent predictors of chest/other infections severity scores. Neither smoking status nor 
alcohol consumption appeared to be significant risk factors for any of the six patterns.  
Associations with patient reported health outcomes 
The CVD pattern was associated with poorer physical health scores (p=0.02), higher odds of 
functional impairment (p=0.02) and hospitalisation (p<0.001) and higher number of GP visits 
(p<0.001; Table 3). Higher STDs severity scores were associated with better physical health 
(p<0.001) and a lower number of GP visits (p<0.001). In addition, weaker evidence was 
found regarding their association with a lower risk of functional impairment (p=0.08) and a 
higher risk of hospitalization (p=0.12). 
The mental health pattern was negatively associated with all the outcomes considered (all 
p’s<0.001), in particular with poorer physical [β (95% conf. int.): -2.62 (-3.40, -1.84)] and 
mental [β (95% conf. int.): -5.46 (-6.19, -4.72)] health scores and increased odds of 
functional impairment [OR (95% conf. int.): 1.88 (1.53, 2.32)]. Significantly poorer physical 
health scores (p=0.03) and a higher risk of functional impairment (p=0.01) were observed for 
the cancers pattern. Higher metabolic severity scores were associated with better physical 
(p=0.04) and mental (p=0.04) health and lower risk of functional impairment (p=0.007).  
Finally, the chest/other infections pattern was negatively associated with all the outcomes. 
Higher severity scores were particularly associated with poorer physical health [β (95% conf. 
int.): 9.15 (-11.74, -6.56), p<0.001], an almost 5-time higher risk of functional impairment 
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[OR (95% conf. int.): 4.83 (2.54, 9.17), p<0.001] and a higher number of GP visits [IRR 
(95% conf. int.): 1.45 (1.24, 1.69), p<0.001]. Also significant were the associations with 
mental health (p=0.03) and hospitalization (p=0.02).  
Discussion 
Common patterns of comorbidities seen in PLWH appear to have different HIV-related and 
non-HIV-related risk factors and demonstrate different associations with quality of life, 
functional status and healthcare resource use.  
As we previously reported [5], disease patterns identified are consistent with those reported 
by other studies in PLWH [10] and in the general population [21-23] with the addition of the 
pattern of STDs, reflecting the high exposure to risk-taking sexual behaviours that is 
prevalent in PLWH [25]. Associations with risk factors varied from pattern to pattern with 
several associations reflecting previously known risk factors, for example BMI and age for 
both CVDs and metabolic disorders. STDs were more prevalent in MSM and PLWH with a 
history of injection drug use, consistent with reports of high-risk sexual behaviours in both 
groups [24, 25]. Injection drug use was also associated with mental health pattern severity. 
Whilst it is not possible to determine the direction of associations seen, evidence suggests 
that mental health problems can both lead to, and be a consequence of, injection drug use 
[26]]. Age and BMI were associated with both the cancers and the chest/other infections 
pattern severity scores, however strong links with these patterns were also observed for HIV-
specific factors such as the time since HIV diagnosis and prior clinical AIDS. AIDS-defining 
malignancies were considered separately from the three cancers that form the pattern (i.e. 
skin cancer, hematological and solid organ cancers). Therefore, this could reflect a genuine 
association where prolonged immune activation and inflammation and/or severe 
immunosuppression may have contributed to an increased burden of non-AIDS-defining 
cancers, as also suggested by a previous study [27]. Moreover, the time since HIV diagnosis 
and a prior AIDS diagnosis were associated with other patterns (CVDs, mental health and 
metabolic), independently of age, suggesting a link between persistent immune activation and 
inflammation with CVDs and metabolic disorders as well as with mental health problems. 
In contrast to what would be expected, neither tobacco smoking nor alcohol consumption 
were identified as potential risk factors for any pattern. This could reflect the generally 
moderate frequency of smoking and alcohol consumption in POPPY PLWH [the median 
(IQR) self-reported number of cigarettes smoked per day and units of alcohol consumed per 
week were 10 (5, 20) and 7 (2, 18), respectively]. Alternatively the lack of association could 
reflect reverse causation due to most comorbidities preceding the time when smoking and 
alcohol consumption were assessed (i.e. at baseline study visit). Current alcohol abstinence 
and/or non-smoking status may reflect previous hazardous over consumption which may 
have led to disorders which, in turn, may have caused people to stop smoking and/or 
consuming alcohol.   
Patterns were also significantly associated with health outcomes with differential effects from 
pattern to pattern. Of the six patterns identified, chest/other infections demonstrated the 
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strongest associations with patient-reported physical health, functional impairment and 
hospitalization. Several of the infections included in this pattern, cytomegalovirus in 
particular, have been reported to act as pro-inflammatory agents, also involved in the process 
of chronic inflammation [28, 29]. Given its association with age, time since HIV diagnosis 
and prior AIDS, this pattern is likely to be accompanied by prolonged immune activation and 
inflammation which, in turn, may have led to poorer physical health and functional 
limitations as also shown in different settings [30, 31]. The mental health pattern showed 
strong associations with all health outcomes considered, independently from the associations 
between mental health and other patterns. Beside the expected link with patient-reported 
mental health, these results seem to support a strong link with physical functioning and 
healthcare resource use. Interestingly, the STDs pattern appeared to be associated with better 
physical health and a lower number of GP visits, once accounting for the severity of the other 
patterns. Whilst results seem to suggest a positive effect, they should be read with caution as 
they are relative to the severity of other patterns and also to the average outcomes seen in the 
cohort. Nevertheless, this apparently positive effect may reflect the fact that treated STDs 
may no longer pose a serious health danger and/or PLWH with multiple STDs may be 
healthier overall than their counterparts with other patterns of comorbidities, such as CVDs or 
mental health disorders. 
There are some limitations to our study that need to be considered. First, since there is not a 
uniform list of comorbidities and medical conditions to define multimorbidity, the list of 
comorbidities considered here can be debated. Some comorbidities may have been missed; 
some of those considered require a medical diagnosis, while others consist more of symptoms 
and were therefore less objectively defined. Second, although the self-reported nature of data 
collection may have led to under or over reporting of some comorbidities, our approach 
consisted in a structured interview conducted by trained staff to ensure consistency across 
study participants and that allowed to capture all the comorbidities with same standardized 
procedure. Thirdly, the cross-sectional nature of the analysis does not permit an assessment 
of causality or the direction of the associations seen (and whether they are bidirectional); 
longitudinal studies are on plan and would allow to shed light on the direction of associations. 
Finally, our cohort was designed to be representative of the population of PLWH seen in care 
in UK and Ireland, predominantly characterized by white MSM; therefore, results could be 
less generalizable to populations of PLWH within different HIV epidemic settings.   
With an increasingly ageing population of PLWH [33] and the consequent increase in the 
prevalence of multimorbidity [34], these findings highlight the need for targeted interventions 
and guidelines for the prevention, diagnosis, treatment and prognosis of multimorbidity in 
PLWH. The identification of risk factors for specific patterns of comorbidities could help the 
development of targeted interventions towards modifiable risk factors in PLWH presenting 
with one or more of the comorbidities in the pattern to prevent the onset of new comorbidities 
that are likely to co-occur with the existing ones. Similarly, treatment of comorbidities in 
patterns with the highest impact on quality of life and healthcare resource use could lead to 
potential benefits for both the patient and the healthcare system. Further longitudinal studies 
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are justified to assess the change over time in patterns’ severity and to elucidate the causal 
link with health outcomes.  
Acknowledgements 
We are grateful to Sebastian Verboeket, Ferdinand Wit and Peter Reiss for their helpful 
comments and insight on previous works that led to this study.  
We also thank all participants and staff involved in the POPPY study. POPPY Management 
Team: Marta Boffito, Paddy Mallon, Frank Post, Caroline Sabin, Memory Sachikonye, Alan 
Winston, Amalia Ndoutoumou, Daphne Babalis. POPPY Scientific Steering Committee: Jane 
Anderson, David Asboe, Marta Boffito, Lucy Garvey, Paddy Mallon, Frank Post, Anton 
Pozniak, Caroline Sabin, Memory Sachikonye, Jaime Vera, Ian Williams, Alan Winston. 
POPPY Sites and Trials Unit (alphabetical): Caldecot Centre, King’s College Hospital (Frank 
Post, Lucy Campbell, Selin Yurdakul, Sara Okumu, Louise Pollard, Beatriz Santana Suárez), 
Department of Infection and Population Health, University College London (Ian Williams, 
Damilola Otiko, Laura Phillips, Rosanna Laverick, Michelle Beynon, Anna-Lena Salz, 
Abigail Severn), Elton John Centre, Brighton and Sussex University Hospital (Martin Fisher, 
Amanda Clarke, Jaime Vera, Andrew Bexley, Celia Richardson, Sarah Kirk, Rebecca Gleig), 
HIV Molecular Research Group, School of Medicine, University College Dublin (Paddy 
Mallon, Alan Macken, Bijan Ghavani-Kia, Joanne Maher, Maria Byrne, Ailbhe Flaherty, 
Aoife McDermott), Homerton Sexual Health Services, Homerton University Hospital (Jane 
Anderson, Sifiso Mguni, Rebecca Clark, Rhiannon Nevin-Dolan, Sambasivarao Pelluri), Ian 
Charleson Day Centre, Royal Free Hospital (Margaret Johnson, Nnenna Ngwu, Nargis 
Hemat, Anne Carroll, Sabine Kinloch, Mike Youle and Sara Madge), Imperial Clinical Trials 
Unit, Imperial College London (Amalia Ndoutoumou, Daphne Babalis), St. Mary’s Hospital 
London, Imperial College Healthcare NHS Trust (Alan Winston, Lucy Garvey, Jonathan 
Underwood, Lavender Tembo, Matthew Stott, Linda McDonald, Felix Dransfield), St 
Stephen's Centre, Chelsea and Westminster Hospital (Marta Boffito, David Asboe, Anton 
Pozniak, Margherita Bracchi, Nicole Pagani, Maddalena Cerrone, Daniel Bradshaw, 
Francesca Ferretti, Chris Higgs, Elisha Seah, Stephen Fletcher, Michelle Anthonipillai, 
Ashley Moyes, Katie Deats, Irtiza Syed, Clive Matthews, Peter Fernando). POPPY 
methodology/statistics/analysis: Caroline Sabin, Davide De Francesco, Emmanouil Bagkeris.  
We acknowledge the use of the NIHR/Wellcome Trust Clinical Research Facility at King’s 
College Hospital. All the POPPY clinical sites in the UK are grateful for NIHR Clinical 
Research Network (CRN) support. 
Authors' contributions  
D.D.F. contributed to study concept and design, literature search, data analysis and 
interpretation, figures, writing of the manuscript. P.W.G.M., A.W., C.A.S. contributed to 
study concept and design, data collection and interpretation, critical revision of manuscript. 
E.B. contributed to data analysis and interpretation, critical revision of the manuscript. J.U., 
J.A. and F.A.P. contributed to data collection and critical revision of manuscript. I.W., 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
J.H.V., M.B., M.J. contributed to data collection. All authors read and approved the final 
manuscript. 
Funding 
The POPPY study is funded from investigator initiated grants from BMS, Gilead Sciences, 
Janssen, MSD and ViiV Healthcare (EudraCT Number: 2012-003581-40; Sponsor Protocol 
Number: CRO1992). The research is supported by the National Institute for Health Research 
(NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and 
Imperial College London. The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the department of Health. 
Conflicts of Interest 
J.A. has accepted fees for consultancy and educational activities from Gilead Sciences, Merk 
Sharp and Dohm, ViiV healthcare, Bristol Myers Squibb, Janssen and KPMG. C.A.S. has 
received funding from Gilead Sciences, ViiV Healthcare, and Janssen-Cilag for membership 
of data safety and monitoring boards, advisory boards, and speaker panels and for preparation 
of educational materials. F.A.P has received research grants from Gilead Sciences and ViiV 
Healthcare, and fees from Gilead Sciences, ViiV Healthcare, MSD and Janssen for 
membership of Advisory Boards, Speaker Panels and/or for the preparation of educational 
materials. P.W.G.M. has received funding for Advisory Boards, speaker panels, preparation 
of educational materials and/or research grants to his institution from Gilead Sciences, ViiV 
Healthcare, BMS, MSD, Abbvie and Janssen-Cilag. 
  
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
References 
1. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive 
individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 
(London, England) 2014; 28(8): 1193. 
2. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing 
population infected with HIV: a modelling study. The Lancet Infectious Diseases 2015; 
15(7): 810-8. 
3. Smit M, Cassidy R, Cozzi-Lepri A, et al. Projections of non-communicable disease and 
health care costs among HIV-positive persons in Italy and the USA: A modelling study. 
PloS one 2017; 12(10): e0186638. 
4. d'Arminio Monforte A, Diaz‐Cuervo H, De Luca A, et al. Evolution of major 
non‐HIV‐related comorbidities in HIV‐infected patients in the Italian Cohort of 
Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 
2004–2014. HIV medicine 2018. 
5. De Francesco D, Verboeket SO, Underwood J, et al. Patterns of co-occurring 
comorbidities in people living with HIV. In: Open forum infectious diseases: Oxford 
University Press US, 2018:ofy272. 
6. Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of 
multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of 
people aged 65–74 years and more than 75 years. BMC geriatrics 2018; 18(1): 99. 
7. Hasse B, Tarr PE, Marques-Vidal P, et al. Strong impact of smoking on multimorbidity 
and cardiovascular risk among human immunodeficiency virus-infected individuals in 
comparison with the general population. In: Open forum infectious diseases: Oxford 
University Press, 2015. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
8. Guaraldi G, Zona S, Brothers TD, et al. Aging with HIV vs. HIV seroconversion at older 
age: a diverse population with distinct comorbidity profiles. PloS one 2015; 10(4): 
e0118531. 
9. Maciel RA, Klück HM, Durand M, Sprinz E. Comorbidity is more common and occurs 
earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 
years and older: A cross-sectional study. International Journal of Infectious Diseases 
2018; 70: 30-5. 
10. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and 
treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. 
Aids 2005; 19: S99-S105. 
11. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: 
the role of obesity in chronic disease clustering. Journal of acquired immune deficiency 
syndromes (1999) 2012; 61(5): 600. 
12. Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected 
with HIV: increased burden with older age and negative effects on health-related quality 
of life. AIDS patient care and STDs 2013; 27(1): 5-16. 
13. Van Duin MJ, Conde R, Wijnen B, et al. The impact of comorbidities on costs, utilities 
and health-related quality of life among HIV patients in a clinical setting in Bogotá. 
Expert Review of Pharmacoeconomics & Outcomes Research 2016: 1-8. 
14. Bagkeris E, Burgess L, Mallon PW, et al. Cohort profile: The Pharmacokinetic and 
clinical Observations in PeoPle over fiftY (POPPY) study. International Journal of 
Epidemiology 2018: dyy072-dyy. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
15. Revelle W, Rocklin T. Very simple structure: An alternative procedure for estimating the 
optimal number of interpretable factors. Multivariate Behavioral Research 1979; 14(4): 
403-14. 
16. The UK Collaborative HIV Cohort Study website. Available at: 
http://www.ctu.mrc.ac.uk/UKCHIC/indexUKCHIC.asp. Accessed 19 May. 
17. McGettrick P, Ghavami-Kia B, Tinago W, et al. The HIV Care Cascade and sub-analysis 
of those linked to but not retained in care: the experience from a tertiary HIV referral 
service in Dublin Ireland. HIV Clinical Trials 2017; 18(3): 93-9. 
18. Dominguez KL, Glynn MK, McKenna MT, Mitsch A, Schneider E, Whitmore S. Revised 
surveillance case definitions for HIV infection among adults, adolescents, and children 
aged< 18 months and for HIV infection and aids among children aged 18 months to< 13 
years---United States, 2008. 2008. 
19. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. 
Conceptual framework and item selection. Medical care 1992: 473-83. 
20. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental 
Activities of Daily Living1. The Gerontologist 1969; 9(3_Part_1): 179-86. 
21. Holden L, Scuffham PA, Hilton MF, Muspratt A, Ng S-K, Whiteford HA. Patterns of 
multimorbidity in working Australians. Population Health Metrics 2011; 9(1): 15. 
22. Schäfer I, von Leitner E-C, Schön G, et al. Multimorbidity Patterns in the Elderly: A New 
Approach of Disease Clustering Identifies Complex Interrelations between Chronic 
Conditions. PLOS ONE 2011; 5(12): e15941. 
23. Prados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, et al. Multimorbidity Patterns 
in Primary Care: Interactions among Chronic Diseases Using Factor Analysis. PLOS 
ONE 2012; 7(2): e32190. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
24. Mansergh G, Marks G. Age and risk of HIV infection in men who have sex with men. 
Aids 1998; 12(10): 1119-28. 
25. Watkins KE, David Metzger B, Woody G, McLellan AT. High-risk sexual behaviors of 
intravenous drug users in-and out-of-treatment: implications for the spread of HIV 
infection. The American journal of drug and alcohol abuse 1992; 18(4): 389-98. 
26. Croughan J, Miller J, Wagelin D, Whitman B. Psychiatric illness in male and female 
narcotic addicts. The Journal of clinical psychiatry 1982; 43(6): 225-8. 
27. Shiels MS, Althoff KN, Pfeiffer RM, et al. HIV infection, immunosuppression, and age at 
diagnosis of non-AIDS-defining cancers. Clinical Infectious Diseases 2017; 64(4): 468-
75. 
28. Söderberg‐Nauclér C. Does cytomegalovirus play a causative role in the development of 
various inflammatory diseases and cancer? Journal of internal medicine 2006; 259(3): 
219-46. 
29. Aiello AE, Haan MN, Blythe L, Moore K, Gonzalez JM, Jagust W. The influence of 
latent viral infection on rate of cognitive decline over 4 years. Journal of the American 
Geriatrics Society 2006; 54(7): 1046-54. 
30. Aiello AE, Haan MN, Pierce CM, Simanek AM, Liang J. Persistent infection, 
inflammation, and functional impairment in older Latinos. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences 2008; 63(6): 610-8. 
31. Büla CJ, Ghilardi G, Wietlisbach V, Petignat C, Francioli P. Infections and functional 
impairment in nursing home residents: a reciprocal relationship. Journal of the American 
Geriatrics Society 2004; 52(5): 700-6. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
32. Kirchberger I, Meisinger C, Heier M, et al. Patterns of Multimorbidity in the Aged 
Population. Results from the KORA-Age Study. PLOS ONE 2012; 7(1): e30556. 
33. van Sighem A, Boender S, Wit FW, Smit C, Matser A, Reiss P. Monitoring Report 2016. 
Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Amsterdam: 
Stichting HIV Monitoring, 2016. 
34. Lachaine J, Baribeau V, Lorgeoux R, Tossonian H. Health Care Resource Utilization And 
Costs Associated With HIV-Positive Patients With Comorbidity Versus HIV-Negative 
Patients With Comorbidity. Value in Health 2017; 20(9): A791. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Tables 
Table 1: Characteristics of study participants 






Male 914 (85.2%) 612 (87.5%) 302 (80.8%)
Female 159 (14.8%) 87 (12.5%) 72 (19.2%)
Age [years] 52 (47, 59) 57 (53, 62) 43 (37, 47)
Ethnicity  
Black-African 171 (15.9%) 96 (13.7%) 75 (19.8%)
White 902 (84.1%) 603 (86.3%) 299 (80.2%)
Sexual orientation  
MSM/homosexual 816 (76.0%) 548 (78.4%) 268 (71.7%)
Heterosexual 257 (24.0%) 151 (21.6%) 106 (28.3%)
BMI [kg/m2] 25.5 (23.2, 28.2) 25.7 (23.4, 28.5)  25.2 (23.0, 27.8)
Smoking  
Smoker 267 (24.9%) 158 (22.6%) 109 (29.1%)
Ex-smoker 365 (34.0%) 263 (37.6%) 102 (27.3%)
Never smoked 436 (40.6%) 275 (39.4%) 161 (43.1%)
Alcohol consumption  
Current consumption 858 (80.0%) 555 (79.4%) 303 (81.0%)
Previous consumption only 125 (11.6%) 87 (12.4%) 38 (10.2%)
Never consumed 90 (8.4%) 57 (8.2%) 33 (8.8%)
Recreational drug use 307 (28.6%) 177 (25.3%) 130 (34.8%)
History of ID use 112 (10.5%) 62 (8.9%) 50 (13.5%)
Duration of HIV [years] 13.2 (7.8, 20.5) 15.8 (9.8, 22.4) 9.7 (5.5, 15.2)
CD4+ T cell count [cells/mm3] 624 (476, 811) 610 (468, 792) 661 (500, 847)
Nadir CD4+ count [cells/mm3] 202 (101, 304) 180 (85, 273) 253 (152, 376)
Prior AIDS 311 (29.0%) 241 (34.5%) 70 (18.7%)
On ART 1046 (97.5%) 690 (98.7%) 356 (95.2%)
HIV RNA <50 copies/ml 965 (89.9%) 644 (91.8%) 323 (86.4%)
SF-36 physical health score 52.4 (42.3, 56.3) 51.7 (41.9, 56.3) 53.2 (45.7, 56.1)
SF-36 mental health score 51.0 (41.6, 57.2) 51.0 (41.3, 57.2) 50.9 (42.3, 57.0)
Functional impairment 148 (14.5%) 108 (16.2%) 40 (11.3%)
Number of GP visit in the last 
year 1 (1, 2) 1 (1, 3) 1 (0, 2)
Hospitalized in the last year 697 (65.0%) 479 (68.5%) 218 (58.3%)
IQR: interquartile range; MSM: men having sex with men; BMI: body-mass index; ART: 
antiretroviral therapy; ID: injection drug 
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Table 2: Regression coefficients (with 95% confidence interval) and associated p-value from 
separate multivariable median regression models predicting patterns’ severity scores 
Risk factor 
Severity score 
















































































































































































































































Recreational -0.01 (- 0.23 (- 0.04 (- 0.03 -0.05 (- 0.03 (-
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Note: physical and mental health scores were analyzed using linear regression; functional 
impairment (yes vs. no) and hospitalization in the last year (yes vs. no) were analyzed using 
binary logistic regression; number of GP visits over the past year was analyzed using Poisson 
regression. 
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Figure legends 
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